kaonavi
4435
D. Western Therapeutics Institute
4576
Itamiarts
168A
Nakayo
6715
Allied Telesis Holdings KK
6835
(Q1)Dec 31, 2024 | (FY)Sep 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 14.64%27.96B | 51.49%107.78B | 76.01%26.3B | 40.06%24.39B | 20.20%71.15B | 23.11B | -4.10%15.68B | -3.35%14.94B | 11.12%17.42B | 296.63%59.19B |
Cost of revenue | 32.44%17.98B | 54.85%69.44B | 86.92%16.63B | 65.85%13.58B | 10.54%44.84B | 18.1B | -12.08%9.66B | -19.05%8.9B | -22.73%8.19B | 1,149.66%40.56B |
Gross profit | -7.71%9.98B | 45.76%38.35B | 59.97%9.67B | 17.19%10.81B | 41.22%26.31B | 5.02B | 12.24%6.02B | 35.26%6.05B | 81.76%9.23B | 59.53%18.63B |
Operating expense | -7.78%2.3B | 20.79%9.71B | 27.24%2.3B | 16.71%2.49B | 16.82%8.04B | 2.14B | 14.82%1.95B | 6.41%1.81B | 27.75%2.14B | 6.83%6.88B |
Operating profit | -7.69%7.68B | 56.76%28.63B | 73.96%7.37B | 17.33%8.32B | 55.52%18.27B | 2.87B | 11.04%4.07B | 52.98%4.24B | 108.28%7.09B | 124.40%11.75B |
Net non-operating interest income (expenses) | -179.13%-91M | 121.40%61M | 132.89%49M | 705.26%115M | -58.33%-285M | -99M | 10.00%-18M | -325.71%-149M | 58.70%-19M | 47.98%-180M |
Non-operating interest income | -11.19%238M | 0.26%781M | 27.91%165M | 37.44%268M | 232.91%779M | --291M | 82.22%164M | 214.63%129M | 290.00%195M | -41.65%234M |
Non-operating interest expense | 115.03%329M | -32.33%720M | -58.27%116M | -28.50%153M | 157.63%1.06B | --390M | 66.97%182M | 265.79%278M | 122.92%214M | -44.71%413M |
Total other finance cost | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1M |
Net investment income | 97.26%-9M | 45.04%-865M | 24.41%-192M | -0.61%-329M | -1,200.70%-1.57B | -751M | -229.41%-242M | -361.86%-254M | -1,357.69%-327M | 121.28%143M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -79.23%27M | 101.31%308M | 300.00%104M | 233.33%130M | -78.30%153M | 46M | -78.46%42M | -84.34%26M | -78.45%39M | -38.21%705M |
Income from associates and other participating interests | -59.05%95M | 63.06%362M | 740.00%42M | 127.45%232M | 484.21%222M | 80M | -33.96%35M | 110.87%5M | 277.78%102M | -74.15%38M |
Special income (charges) | 0 | 383.90%582M | 0 | 262.57%569M | -130.34%-205M | -125M | 687.23%276M | -6M | -17,400.00%-350M | 88.04%-89M |
Less:Impairment of capital assets | --0 | -90.63%12M | --0 | --12M | --128M | ---- | ---- | --0 | --0 | --0 |
Less:Other special charges | ---- | -112.50%-595M | --0 | -29,150.00%-581M | -1,966.67%-280M | ---10M | ---281M | --9M | 0.00%2M | -93.59%15M |
Less:Write off | ---- | -99.72%1M | --0 | --0 | 382.43%357M | --7M | -89.36%5M | ---3M | --348M | -76.73%74M |
Other non-operating income (expenses) | 96.15%255M | -71.90%360M | -94.18%17M | -15.03%130M | 1,763.64%1.28B | 535M | 204.04%301M | 370.37%292M | 482.50%153M | 64.68%-77M |
Income before tax | -13.22%7.96B | 64.88%29.44B | 78.02%7.39B | 37.12%9.17B | 45.36%17.86B | 2.56B | 8.15%4.46B | 45.92%4.15B | 88.31%6.69B | 170.51%12.28B |
Income tax | -10.54%2.45B | 67.46%8.97B | 94.33%2.26B | 29.20%2.74B | 39.33%5.36B | 688M | 2.98%1.38B | 18.55%1.16B | 109.58%2.12B | 142.07%3.84B |
Net income | -14.35%5.5B | 63.79%20.47B | 71.73%5.13B | 40.78%6.43B | 48.11%12.5B | 1.87B | 10.63%3.08B | 60.28%2.99B | 79.90%4.56B | 185.87%8.44B |
Net income continuous operations | -14.36%5.5B | 63.78%20.47B | 71.68%5.13B | 40.80%6.43B | 48.10%12.5B | --1.87B | 10.64%3.08B | 60.33%2.99B | 79.83%4.56B | 185.81%8.44B |
Noncontrolling interests | -16.67%35M | -54.55%15M | -283.33%-11M | 1,300.00%42M | 191.67%33M | 10M | 151.85%14M | 118.18%6M | -82.35%3M | -820.00%-36M |
Net income attributable to the company | -14.34%5.47B | 64.10%20.46B | 72.39%5.14B | 39.96%6.38B | 47.09%12.47B | 1.86B | 9.04%3.07B | 57.06%2.98B | 81.02%4.56B | 187.68%8.48B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -14.34%5.47B | 64.10%20.46B | 72.39%5.14B | 39.96%6.38B | 47.09%12.47B | 1.86B | 9.04%3.07B | 57.06%2.98B | 81.02%4.56B | 187.68%8.48B |
Gross dividend payment | ||||||||||
Basic earnings per share | -13.35%64.76 | 64.47%240.07 | 72.41%60.17 | 39.96%74.74 | 47.09%145.97 | 21.77 | 9.09%35.9 | 57.07%34.9 | 81.02%53.4 | 187.57%99.24 |
Diluted earnings per share | -13.35%64.76 | 64.47%240.07 | 72.41%60.17 | 39.96%74.74 | 47.09%145.97 | 21.77 | 9.05%35.8887 | 57.07%34.9 | 81.02%53.4 | 187.57%99.24 |
Dividend per share | 0 | 64.79%120.3 | 38.75 | 0 | 46.00%73 | 73 | 0 | 0 | 0 | 203.03%50 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |